ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma.
In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1] R-ESHAP consists of: